JP6144689B2 - Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法 - Google Patents

Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法 Download PDF

Info

Publication number
JP6144689B2
JP6144689B2 JP2014541298A JP2014541298A JP6144689B2 JP 6144689 B2 JP6144689 B2 JP 6144689B2 JP 2014541298 A JP2014541298 A JP 2014541298A JP 2014541298 A JP2014541298 A JP 2014541298A JP 6144689 B2 JP6144689 B2 JP 6144689B2
Authority
JP
Japan
Prior art keywords
vegf
antibody
antigen
seq
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014541298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534237A (ja
JP2014534237A5 (enExample
Inventor
リー・チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2014534237A publication Critical patent/JP2014534237A/ja
Publication of JP2014534237A5 publication Critical patent/JP2014534237A5/ja
Application granted granted Critical
Publication of JP6144689B2 publication Critical patent/JP6144689B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014541298A 2011-11-10 2012-11-09 Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法 Active JP6144689B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161557939P 2011-11-10 2011-11-10
US61/557,939 2011-11-10
US201261609968P 2012-03-13 2012-03-13
US61/609,968 2012-03-13
US201261613538P 2012-03-21 2012-03-21
US61/613,538 2012-03-21
PCT/US2012/064311 WO2013071016A2 (en) 2011-11-10 2012-11-09 Methods of inhibiting tumor growth by antagonizing il-6 receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017000818A Division JP6283754B2 (ja) 2011-11-10 2017-01-06 Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法

Publications (3)

Publication Number Publication Date
JP2014534237A JP2014534237A (ja) 2014-12-18
JP2014534237A5 JP2014534237A5 (enExample) 2015-10-29
JP6144689B2 true JP6144689B2 (ja) 2017-06-07

Family

ID=47179020

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014541298A Active JP6144689B2 (ja) 2011-11-10 2012-11-09 Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法
JP2017000818A Active JP6283754B2 (ja) 2011-11-10 2017-01-06 Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法
JP2018011135A Withdrawn JP2018083841A (ja) 2011-11-10 2018-01-26 Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017000818A Active JP6283754B2 (ja) 2011-11-10 2017-01-06 Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法
JP2018011135A Withdrawn JP2018083841A (ja) 2011-11-10 2018-01-26 Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法

Country Status (20)

Country Link
US (3) US20130122003A1 (enExample)
EP (1) EP2776468B1 (enExample)
JP (3) JP6144689B2 (enExample)
KR (1) KR101718748B1 (enExample)
CN (1) CN103930443B (enExample)
AR (1) AR088671A1 (enExample)
AU (2) AU2012335596B2 (enExample)
BR (1) BR112014011211A2 (enExample)
CA (1) CA2853836C (enExample)
IL (2) IL231854A (enExample)
IN (1) IN2014CN02923A (enExample)
JO (1) JO3370B1 (enExample)
MX (1) MX357837B (enExample)
MY (1) MY163953A (enExample)
RU (1) RU2648150C2 (enExample)
SG (1) SG11201401286QA (enExample)
TW (3) TW201806620A (enExample)
UY (1) UY34444A (enExample)
WO (1) WO2013071016A2 (enExample)
ZA (1) ZA201402414B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
WO2015000181A1 (zh) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP3161000A4 (en) * 2014-06-28 2018-05-02 Kodiak Sciences Inc. Dual pdgf/vegf antagonists
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016196377A1 (en) * 2015-05-29 2016-12-08 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
CN112203679A (zh) * 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
AU2019235782A1 (en) 2018-03-14 2020-10-08 Celledit Llc Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
CN108567981A (zh) * 2018-07-17 2018-09-25 漯河医学高等专科学校 白细胞介素-6的拮抗剂在制备抑制Notch-1蛋白表达、治疗胰腺癌的药物中的应用
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN113677356A (zh) * 2019-01-07 2021-11-19 湖南思为康医药有限公司 用于降低毒性的共表达嵌合抗原受体和il-6拮抗剂的修饰免疫细胞及其在过继细胞疗法中的用途
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
EP4298127A4 (en) * 2021-02-27 2025-04-23 Eluminex Biosciences (Suzhou) Limited Antibody fusion proteins targeting il-6 receptor and angiogenic factors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
ATE214602T1 (de) 1994-12-29 2002-04-15 Chugai Pharmaceutical Co Ltd Verstärker eines anti-tumoragens beinhaltend einen il-6 antagonisten
US5795695A (en) 1996-09-30 1998-08-18 Xerox Corporation Recording and backing sheets containing linear and cross-linked polyester resins
BRPI0011407B8 (pt) * 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
ATE316531T1 (de) 1999-10-07 2006-02-15 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
AU2000279624A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR20060079180A (ko) * 2003-07-02 2006-07-05 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
BRPI0415505A (pt) 2003-10-17 2006-12-12 Chugai Pharmaceutical Co Ltd agente terapêutico para mesotelioma
US20090269335A1 (en) 2005-11-25 2009-10-29 Keio University Therapeutic agent for prostate cancer
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
CN102292449B (zh) * 2008-11-25 2016-03-30 奥尔德生物制药公司 预防或治疗血栓形成的il-6拮抗剂
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Also Published As

Publication number Publication date
ZA201402414B (en) 2015-03-25
EP2776468A2 (en) 2014-09-17
TW201806620A (zh) 2018-03-01
TW201332569A (zh) 2013-08-16
RU2648150C2 (ru) 2018-03-22
US9409990B2 (en) 2016-08-09
US20130122003A1 (en) 2013-05-16
JP2017095489A (ja) 2017-06-01
SG11201401286QA (en) 2014-05-29
CN103930443B (zh) 2017-08-04
TWI604852B (zh) 2017-11-11
US20170022279A1 (en) 2017-01-26
MY163953A (en) 2017-11-15
WO2013071016A3 (en) 2013-07-25
WO2013071016A2 (en) 2013-05-16
JO3370B1 (ar) 2019-03-13
RU2014118739A (ru) 2015-12-20
IN2014CN02923A (enExample) 2015-07-03
KR20140095481A (ko) 2014-08-01
CA2853836A1 (en) 2013-05-16
IL248620A0 (en) 2016-12-29
KR101718748B1 (ko) 2017-03-22
TW201716776A (zh) 2017-05-16
US20140322215A1 (en) 2014-10-30
MX357837B (es) 2018-07-26
EP2776468B1 (en) 2018-01-24
JP6283754B2 (ja) 2018-02-21
IL231854A0 (en) 2014-05-28
UY34444A (es) 2013-05-31
JP2014534237A (ja) 2014-12-18
AU2012335596B2 (en) 2018-05-17
AU2018203666A1 (en) 2018-06-14
CN103930443A (zh) 2014-07-16
JP2018083841A (ja) 2018-05-31
AR088671A1 (es) 2014-06-25
MX2014004886A (es) 2014-07-09
IL231854A (en) 2016-11-30
BR112014011211A2 (pt) 2017-04-25
AU2012335596A1 (en) 2014-05-22
CA2853836C (en) 2019-07-23

Similar Documents

Publication Publication Date Title
JP6283754B2 (ja) Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法
US11655291B2 (en) Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A
JP6486268B2 (ja) 抗ｅｇｆｒ抗体及びその使用
US20160152717A1 (en) Methods for treating dry eye disease by administering an il-6r antagonist
JP2021515003A (ja) 体組成を変更するための方法
HK1197681A (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
HK1197681B (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
HK1202559B (en) Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170414

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170511

R150 Certificate of patent or registration of utility model

Ref document number: 6144689

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250